Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, USA) and Prof Oliver Sartor (Tulane Cancer Center, New Orleans, USA) discuss the latest on PARPi and other treatments for mCRPC from ASCO 2021.
Dr Shore begins the conversation by introducing himself and Prof Sartor and then they talk about the role of PARP inhibitors for mCRPC. They talk about the efficacy of olaparib, cabazitaxel and talazoparib.
They then mention a study dealing with differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients.
Dr Shore also discusses the ACIS study and Prof Sartor explains the TALAPRO-2 study. In the end, Prof Sartor discusses his VISION study that has shown positive results for patients with mCRPC.
|Indirect treatment comparison of the efficacy of olaparib and cabazitaxel for mCRPC|
|Detailed safety analyses from TALAPRO-1 trial|
|Differential responses to taxanes and PARPis in ATM- versus BRCA2-mCRPC patients|
|Analysis of two subgroups in ACIS evaluating APA + AAP versus PBO + AAP in mCRPC|
|Evaluation of PSA progression after initiation of enzalutamide or abiraterone|
|TALAPRO-2: ENZA plus TALA versus placebo in patients with new mCRPC|
|VISION: Phase III study of lutetium-177-PSMA-617 in patients with mCRPC|
To watch a related expert panel discussion on the role of testing in prostate cancer treatment click here.
This programme has been supported by an unrestricted educational grant from AstraZeneca.